The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.

Company Guidance

The company guided that it remains on track for full‑year revenue growth and full‑year positive adjusted EBITDA, expects to close additional data revenue in Q4 (including a closed 6‑figure data deal and incremental revenue from the large data deal announced in Q3 FY25), and sees the payoff from current investments beginning in fiscal 2027 with more meaningful acceleration in fiscal 2028; Corellia funding is included in initial fiscal 2027 budgets (though external financing could redeploy that EBITDA). For context, Q3 results underpinning the guidance included total revenue of $16.6M (down ~3% YoY from $17.0M) driven by record study revenue of $16.6M (+~32% YoY vs $12.6M) and no data revenue this quarter (vs $4.5M prior), adjusted EBITDA of $575K (GAAP loss from operations ≈$275K), gross margin of 47% ($8.8M cost of sales, >$2M of which was outsourced lab work — if performed internally margin would exceed 50%), operating expenses of $7.2M (vs $5.3M), net cash used in operations $1.4M, and $7.1M cash with no debt.

Record Services Revenue and Core Study Growth

Total revenue of $16.6M for the quarter with core study (services) revenue a record $16.6M, up from $12.6M year-ago (~+32%), reflecting strong study execution and conversion of previously booked work.

Positive Adjusted EBITDA Momentum

Third consecutive quarter of positive adjusted EBITDA of $575k, and management remains on track for full-year positive adjusted EBITDA.

Operating Leverage and Efficiency

Growth in services delivered without material additions to headcount, indicating operating leverage and the ability to expand margins as the business scales.

Early Commercial Traction in Data Business

Closed a six-figure data deal in the quarter (expected to be recognized in Q4) and expects incremental revenue from a previously announced large data deal in Q4 — signs of early momentum in the nascent data platform.

Strategic Investments in Growth Vectors

Continued investments in the data platform, sequencing and related R&D, expansion of data business development and commercial teams, and development of radiopharmaceutical capabilities to enhance long-term growth potential.

Progress at Corellia (Target Discovery Subsidiary)

Corellia generating attractive data with positive feedback from potential VC and licensing partners; management plans to include funding in fiscal 2027 budget and may secure external funding to reduce internal EBITDA investment.

Solid Balance Sheet Positioning

Ended the quarter with $7.1M in cash, no debt, and net cash used in operating activities of $1.4M for the quarter, with management stating cash is within projected range.

Champions Oncology (CSBR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSBR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 16, 2026	2026 (Q4)	- / -	-0.07	―	―	―
Mar 12, 2026	2026 (Q3)	0.09 / -0.02	0.36	-105.56% (-0.38)	―
Dec 15, 2025	2026 (Q2)	0.00 / 0.06	0.05	20.00% (<+0.01)	―
Sep 15, 2025	2026 (Q1)	-0.01 / 0.02	0.11	-81.82% (-0.09)	―
Jul 23, 2025	2025 (Q4)	-0.20 / -0.07	0.01	-800.00% (-0.08)	―
Mar 11, 2025	2025 (Q3)	-0.01 / 0.36	-0.16	325.00% (+0.52)	―
Dec 11, 2024	2025 (Q2)	0.01 / 0.05	-0.15	133.33% (+0.20)	―
Sep 11, 2024	2025 (Q1)	-0.03 / 0.11	-0.16	168.75% (+0.27)	―
Jul 18, 2024	2024 (Q4)	-0.16 / 0.01	-0.17	105.88% (+0.18)	―
Mar 12, 2024	2024 (Q3)	-0.06 / -0.16	-0.16	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSBR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 12, 2026	$5.74	$6.10	+6.27%
Dec 15, 2025	$7.80	$6.73	-13.72%
Sep 15, 2025	$6.83	$8.30	+21.52%
Jul 23, 2025	$7.75	$6.65	-14.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Champions Oncology Inc (CSBR) report earnings?

Champions Oncology Inc (CSBR) is schdueled to report earning on Jul 16, 2026, After Close (Confirmed).

What is Champions Oncology Inc (CSBR) earnings time?

Champions Oncology Inc (CSBR) earnings time is at Jul 16, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSBR EPS forecast?

Currently, no data Available